EUVIMEDEUVIMED entdecken
EUVIMED · CrossrefZeitschrift

Future Oncology

ISSN 1479-6694 · Informa UK Limited

Neueste Artikel

  1. Treatment outcomes of tucatinib in combination with trastuzumab and pertuzumab as a maintenance therapy for people with HER2+ metastatic breast cancer: a plain language summary of findings from HER2CLIMB-05

    Veronique Dieras, Giuseppe Curigliano, Miguel Martin, Florence Lerebours, Junji Tsurutani, Marie-France Savard, Katarzyna J. Jerzak, Xichun Hu, Luciana Carla Martins de Aquino Pimentel, Ciara C. O’Sullivan, Eriko Tokunaga, Alicia Okines, Chiun-Sheng Huang, William Jacot, Joohyuk Sohn, Eduardo Cronemberger Silva, Volkmar Muelle, Shan Yang, Giovanna Granata, Qi Shen, Erika Hamilton

    Erschienen: 2026-11-06DOI: 10.1080/14796694.2026.2753928

  2. Study design of the phase III ADELA trial of elacestrant with or without everolimus in ESR1 -mutated ER+/HER2– advanced breast cancer after progression on endocrine therapy plus a CDK4/6 inhibitor

    José Manuel Pérez-García, Antonio Llombart-Cussac, Elena López-Miranda, Alfonso Cortes, Isabel Garcia-Fructuoso, Elena Galve-Calvo, Manuel Ruiz-Borrego, Alba Cochs, Antonia Perelló-Martorell, Serafin Morales, Laia Boronat Ruiz, Sara Marín-Liébana, Cristina Saavedra, Isabel Blancas, Carmen Hinojo, Mariana López Flores, Sylvain Ladoire, Peter Schmid, Gilles Freyer, Rui Rui Zhang, Daniel Alcalá-López, Juliana Carvalho-Santos, Olga Boix, Carlos H. Barrios, Giuseppe Curigliano, Rupert Bartsch, Anne Clair Hardy Bessard, Tomer Wasserman, Javier Cortés

    Erschienen: 2026-10-31DOI: 10.1080/14796694.2026.2753794

  3. Treatment outcomes and quality of life with palbociclib in patients with advanced breast cancer who also have other medical conditions: a plain language summary of findings from POLARIS

    Debu Tripathy, Joanne L. Blum, Meghan S. Karuturi, Steven McCune, Sobha Kurian, Mehdi M. Moezi, Daniel M. Anderson, Yan Ji, Timothy J. Pluard, John Migas, Shailendra Lakhanpal, Erin Jepsen, Yao Wang, Monica Z. Montelongo, Zhe Zhang, Joseph C. Cappelleri, Eric Gauthier, Gabrielle B. Rocque

    Erschienen: 2026-10-08DOI: 10.1080/14796694.2026.2747581

  4. Study protocol of a prospective, non-interventional cohort study evaluating the benefits of transjugular intrahepatic portosystemic shunt in patients with hepatocellular carcinoma receiving first-line atezolizumab plus bevacizumab (NISTIPS TRITICC-4, IKF092)

    Carolin Angendohr, Christian Weigel, Anselm Kunstein, Markus Joerdens, Thorsten Goetze, Salah-Eddin Al-Batran, Bianca Zäpf, Maria Gonzalez-Carmona, Cennet Sahin, Marie-Luise Berres, Friedrich Foerster, Najib Ben Khaled, Christine Koch, Arne Kandulski, Henning Wege, Jonel Trebicka, Leonie S. Jochheim, Michael T. Dill, Christoph Springfeld, Severin Daum, Christoph Treese, Ursula Ehmer, Tom Luedde, Johannes Bode, Christoph Roderburg

    Erschienen: 2026-10-08DOI: 10.1080/14796694.2026.2748246

  5. Plain language summary: comparing ivonescimab plus chemotherapy with placebo plus chemotherapy in people with advanced EGFR-mutated non–small cell lung cancer (NSCLC) whose disease worsened on EGFR-TKI treatment in the HARMONi study

    Xiuning Le, Antonio Passaro, Yuanyuan Zhao, Yan Huang, Janessa Laskin, Delvys Rodriguez-Abreu, Antonio Calles, Lyudmila Bazhenova, Giuseppe Lo Russo, Natasha B. Leighl, Federico Cappuzzo, Nicolas Girard, Sanjay Popat, Wenfeng Fang, Yongzhong Luo, Zhiyong He, Hui Zhao, Mingjun Li, Qibin Song, Hongyun Zhao, Haidar El Darsa, Isabelle Monnet, Manuel Cobo Dols, Rosario García Campelo, Robert Jotte, David Berz, Alexander Spira, Maurice Pérol, Misako Nagasaka, Howard West, Jianling Li, Fong Clow, Amy C. Moore, Jonathan Goldman, Zhang Li

    Erschienen: 2026-10-08DOI: 10.1080/14796694.2026.2749355

  6. Phase 1 study of OX40 agonist ABBV-368 as monotherapy or in combination with budigalimab in advanced solid tumors

    Marc Oliva, John Powderly, Christophe Le Tourneau, Amani Makkouk, Philippe A. Cassier, Maulik Patel, Ki Chung, Alexander Spira, Amita Patnaik, Wu-Chou Su, Toshihiko Doi, Victor Moreno, Chia-Chi Lin, Toshio Shimizu, Sonali Jindal, Padmanee Sharma, Agostina Stradella, Jaehyung Hong, John Engelhardt, Martha Blaney, Tolga Turan, Luija Wang, Michael A. McDevitt, A. Dimitrios Colevas

    Erschienen: 2026-09-26DOI: 10.1080/14796694.2026.2736946

  7. A plain language summary of results from the NeoADAURA study: treatment with osimertinib before surgery for patients with EGFR-mutated non-small cell lung cancer that can be surgically removed

    Jianxing He, Walter Weder, Ke-Neng Chen, Maximilian J. Hochmair, Jin-Yuan Shih, Sung Yong Lee, Kang-Yun Lee, Viet Nhung Nguyen, Somcharoen Saeteng, Lunxu Liu, Ligang Xing, Nguyen Hoang Gia, Shuji Murakami, Yongtao Han, María Paz Saavedra, Seong Hoon Yoon, Carlos H.A. Teixeira, Carles Escriu, Alex Martinez-Martí, Collin M. Blakely, Yasushi Yatabe, Sanja Dacic, Yuri Rukazenkov, Xiangning Huang, Anupriya Dayal, Jamie E. Chaft

    Erschienen: 2026-09-26DOI: 10.1080/14796694.2026.2739188

Jahrgänge

2026 · 1892025 · 3752024 · 3082023 · 2422022 · 4142021 · 4452020 · 3302019 · 3932018 · 3262017 · 3152016 · 3082015 · 3882014 · 2962013 · 2362012 · 1822011 · 1592010 · 1952009 · 1722008 · 932007 · 822006 · 832005 · 98

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.